

Special Issue

Recent Advances in PROteolysis Targeting Chimeras (PROTACs)

Message from the Guest Editors

PROteolysis TARGETing Chimeras (PROTACs) are innovative and exciting technologies that are rapidly gaining traction in both academic research and the pharmaceutical industry. Unlike traditional therapies that aim to inhibit or block the activity of problematic proteins, PROTACs function by degrading the proteins themselves. This unique mechanism opens up new therapeutic possibilities, especially for previously "undruggable" proteins that cannot be effectively targeted using conventional inhibitors. However, despite their promise, there are still several challenges to overcome before PROTACs can fully transition into clinical use. For this Special Issue, we invite submissions of original research and review articles that explore the latest advancements in PROTACs. Topics of interest include the development of novel PROTACs, their roles in overcoming drug resistance, and their applications in various disease contexts. We are also particularly interested in studies focused on drug delivery systems. Submissions that provide laboratory, preclinical, or clinical evidence of PROTACs' potential in cancer therapy and other diseases are highly encouraged.

Guest Editors

Prof. Dr. Dhimant Desai

Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA 17033, USA

Dr. Mourad Zerfaoui

Department of Pediatrics, Laboratory of Biochemical Pharmacology, Emory University School of Medicine, Atlanta, GA, USA

Deadline for manuscript submissions

closed (15 March 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/217918

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)